Companion Diagnostics or Theransotics Products in the Market
Tue, February 14 2012, 12:00 AM Posted By: Sciclips
Following are some of the companion diagnostics or theranostics products that are currently available (may not be available worldwide), in addition to the US FDA approved Genetech's Hercept® with DakoCytomation's HercepTest® for breast cancer and Roche's Zelboraf ® and companion diagnostic test for late-stage skin cancer.
4. AtheroAbzymeTM ELISA (from Cambridge Theranostics) - this test is used for identifying the risk of developing diseases caused by the oxidation of lipids due to the presence of active ALOA (Atherogenic Lipid-Oxidising Antibodies). This test can also be used for monitoring patients who were treated with anti-ALOA.
5. CancerTYPE ID® (from bioTheranostics) - a molecular diagnostic test for the determination of tumor site of origin using differential expression of 92 genes.
6. Breast Cancer IndexSM- (from bioTheranostics) - a prognostic biomarker based test for the quantitative assessment of the likelihood of distant recurrence in estrogen receptor-positive, lymph node-negative breast cancer patients.
7. PRÉCISSM Precision Medicine (from bioTheranostics) - biomarker profiling based test for the detection of clinically relevant tumor biomarkers for non-small cell lung cancer (NSCLC) and colorectal cancer.
11. CVDefine® kit: ELISA based immunoassay kit for the early detection of lesions in the artery wall caused by inflammation (from Athera Biotechnologies AB).
12. Aetiological diagnosis of AKI (from Bio-inRen)- urinary marker based test for monitoring hypertension and antihypertensive therapy efficacy.
13. Acquired risk of kidney injury (from Bio-inRen)- biomarkers based test to detect patients with increased risk of developing acute kidney injury from a drug treatment.
14. InformMDx (from MDxHealth) - prognostic assay for differentiating aggressive and non-aggressive tumors (prostate and lung cancer) (product pipeline).
15. PredictMDx (from MDxHealth) - a predictive test to identify which drug or treatment regimen is likely to be most effective for prostate and lung cancer patients (product pipeline).
On Thu, January 19 2012, 04:22 AM Harish commented on
Cancer Theranostics - Potential Applications of Cancer Biomarker Database"Nice article, very usefull"
